Normalized Income after Taxes: A company's after tax profit or loss smoothed out by elimination of all non-recurring items.
Sutro Biopharma, Inc. (STRO) had Normalized Income after Taxes of $-38.48M for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
$14.52M |
|
$-38.48M |
|
-- |
|
$14.52M |
|
$44.18M |
|
$-29.66M |
|
$-8.84M |
|
$-38.50M |
|
$-38.50M |
|
$-38.48M |
|
$-38.48M |
|
$-38.48M |
|
|
Normalized Income after Taxes |
$-38.48M |
$-29.66M |
|
$-28.82M |
|
13.08M |
|
13.08M |
|
$-2.94 |
|
$-2.94 |
|
| Balance Sheet Financials | |
$220.97M |
|
$9.36M |
|
$21.02M |
|
$241.99M |
|
$70.81M |
|
-- |
|
$238.06M |
|
$308.88M |
|
$-66.89M |
|
$-66.89M |
|
$-66.89M |
|
16.57M |
|
| Cash Flow Statement Financials | |
$-42.26M |
|
$-45.26M |
|
$103.08M |
|
$58.99M |
|
$74.54M |
|
$15.55M |
|
$1.56M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.12 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-204.20% |
|
-204.20% |
|
-- |
|
-265.09% |
|
-264.99% |
|
$-42.27M |
|
-- |
|
-- |
|
-- |
|
0.06 |
|
-- |
|
1.16 |
|
77.36 |
|
57.54% |
|
57.54% |
|
-15.90% |
|
57.54% |
|
$-4.04 |
|
$-3.23 |
|
$-3.23 |
|